AT-527

A leader in the discovery of oral direct-acting antiviral therapies joins the battle against COVID-19.

Atea’s most advanced antiviral drug candidate, AT-527, is being evaluated in a Phase 2 clinical trial in the US for the treatment of patients with moderate COVID-19 and risk factors for poor outcomes. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by markedly inhibiting replication of the SARS-CoV-2 virus.

Learn More

OUR SCIENCE

The power of our purine nucleotide prodrug platform.

Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Designed with unique chemical modifications, they have the potential to enhance the safety and antiviral potency of these therapeutics.

How it Works

A network of hubs and spokes is suspended, representing the idea of a modular platform.

COVID-19

What we're up against.

COVID-19 is a severe global pandemic that continues to spread to new territories at an unprecedented rate. Medical and scientific communities are investigating the clinical manifestations of COVID-19 and the deceptive dimensions of subclinical infection with SARS-CoV-2, the virus responsible for COVID-19.

As a result, our knowledge about the disease and the virus is evolving, often in surprising ways. Stay up-to-date on the latest facts and findings from reputable sources.

About COVID-19

GLOBAL

Health Emergency

HIGH

Transmission Rate

NO

Available Vaccine

NO

Oral Therapeutic*

*There is no FDA-approved, commercially available antiviral medicine for COVID-19. One investigational agent, administered intravenously, is currently available for emergency use under FDA supervision, limited to patients with severe COVID-19 illness.

NEWS

Follow our progress.

See updates on AT-527, other antiviral therapies and company news.

September 14, 2020

Atea Pharmaceuticals Appoints Polly Murphy, D.V.M, Ph.D., to the Board of Directors

Pharmaceutical executive brings 20 years of clinical, commercial and operational leadership BOSTON, Mass., September 14, 2020 – Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next- generation therapeutics for severe viral infections, today announced the appointment of Polly Murphy, D.V.M., Ph.D., Chief Business Officer of…

August 24, 2020

Atea Pharmaceuticals Strengthens Management Team with Appointment of Clinical and Regulatory Leadership

Executive Vice President of Clinical Sciences and Vice President of Regulatory Bring Decades of Clinical and Regulatory Experience BOSTON, Mass., August 24, 2020 – Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointments of Arantxa Horga,…

August 10, 2020

Atea Pharmaceuticals Appoints Janet Hammond, M.D., Ph.D., as Chief Development Officer

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointment of Janet Hammond, M.D., Ph.D., Sc.M., F.C.P., to the newly-created position of Chief Development Officer. Dr. Hammond will be responsible for overseeing Atea’s clinical development programs, specifically spearheading its development of AT-527 for the treatment of COVID-19.

All News & Press Releases